共 50 条
The Year in Cardiology 2013: valvular heart disease (focus on catheter-based interventions)
被引:16
|作者:
Grube, Eberhard
[1
]
Sinning, Jan-Malte
[1
]
Vahanian, Alec
[2
]
机构:
[1] Univ Hosp Bonn, Heart Ctr Bonn, Dept Med 2, D-53105 Bonn, Germany
[2] Univ Paris 07, Bichat Hosp, Dept Cardiol, Paris, France
关键词:
Aortic stenosis;
Aortic regurgitation;
Mitral stenosis;
Mitral regurgitation;
TAVI;
TAVR;
TMVR;
PMC;
MitraClip;
CoreValve;
Edwards-SAPIEN;
Direct Flow Medical Valve;
Boston Lotus Valve;
Paravalvular aortic regurgitation;
Paravalvular leakage;
Stroke;
Annular rupture;
Durability;
Intermediate risk;
Risk;
Outcome;
Co-morbidities;
Frailty;
GARY;
Valve-in-valve;
VIV;
Neworal anticoagulants;
NOAC;
Anticoagulation;
Valvular heart disease;
AORTIC-VALVE-REPLACEMENT;
LOW-FLOW;
CLINICAL-OUTCOMES;
EJECTION FRACTION;
LOW-GRADIENT;
IMPLANTATION;
STENOSIS;
REGURGITATION;
PREDICTORS;
MANAGEMENT;
D O I:
10.1093/eurheartj/eht558
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
2013 was the year of transcatheter heart valve interventions. Not least because of the 2012 European guidelines on the management of valvular heart disease (VHD), the multidisciplinary heart team approach became an established concept. Decision-making, when a patient is too 'sick' for surgery and too 'healthy' for catheter-based interventions, is complex, since VHD is often seen at an older age and, as a consequence, there is a higher frequency of co-morbidity and frailty. However, before TAVI and other transcatheter heart valve interventions can be expanded to intermediate-risk patients, evidence in favour of this less invasive treatment has to be provided by upcoming randomized clinical trials.
引用
收藏
页码:490 / U74
页数:6
相关论文